Evidence map›Paper›PMID 32055309›Full record

ArticleChemical science2019

Assisted delivery of anti-tumour platinum drugs using DNA-coiling gold nanoparticles bearing lumophores and intercalators: towards a new generation of multimodal nanocarriers with enhanced action.

Ana B Caballero, Lucia Cardo, Sunil Claire, James S Craig, Nikolas J Hodges, Anton Vladyka, Tim Albrecht, Luke A Rochford, Zoe Pikramenou, Michael J Hannon

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Ana B CaballeroSchool of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . Email: m.j.hannon@bham.ac.uk ; Email: z.pikramenou@bham.ac.uk.ORCID 0000-0001-9294-9085
Lucia CardoSchool of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . Email: m.j.hannon@bham.ac.uk ; Email: z.pikramenou@bham.ac.uk.ORCID 0000-0003-3387-9667
Sunil ClaireSchool of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . Email: m.j.hannon@bham.ac.uk ; Email: z.pikramenou@bham.ac.uk.
James S CraigPhysical Sciences for Health Centre , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK.ORCID 0000-0001-6128-9117
Nikolas J HodgesSchool of Biosciences , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK.
Anton VladykaSchool of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . Email: m.j.hannon@bham.ac.uk ; Email: z.pikramenou@bham.ac.uk.
Tim AlbrechtSchool of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . Email: m.j.hannon@bham.ac.uk ; Email: z.pikramenou@bham.ac.uk.
Luke A RochfordSchool of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . Email: m.j.hannon@bham.ac.uk ; Email: z.pikramenou@bham.ac.uk.
Zoe PikramenouSchool of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . Email: m.j.hannon@bham.ac.uk ; Email: z.pikramenou@bham.ac.uk.
Michael J HannonSchool of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . Email: m.j.hannon@bham.ac.uk ; Email: z.pikramenou@bham.ac.uk.ORCID 0000-0002-5797-6747
University of Birmingham · GBThe Centre for Health (New Zealand) · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New gold and lipoic based nanocarriers for the delivery of platinum(ii) and platinum(iv) drugs are developed, which allow enhanced loading of the drug on the surface of the nanocarriers and release in a pH-dependent fashion, with superior release at lower pHs which are associated with many tumours. The conjugate nanoparticles and their conjugates enter cells rapidly (within 3 hours). They tend to cluster in vesicles and are also observed by light and electron microscopies in the cytoplasm, endoplasmic reticulum and nucleus. We further incorporate aminoanthraquinone units that are both fluorophores and DNA intercalators. This results in nanocarriers that after drug release will remain surface decorated with DNA-binders challenging the conventional design of the nanocarrier as an inert component. The outcome is nanocarriers that themselves have distinctive, remarkable and unusual DNA binding properties being able to bind and wrap DNA (despite their anionic charge) and provide enhanced cytotoxic activity beyond that conferred by the platinum agents they release. DNA coiling is usually associated with polycations which can disrupt cell membranes; anionic nanoparticles that can cause novel and dramatic effects on DNA may have fascinating potential for new approaches to in-cell nucleic acid recognition. Our findings have implications for the understanding and interpretation of the biological activities of nanoparticles used to deliver other DNA-binding drugs including clinical drug doxorubicin and its formulations.

Identifiers

PMID32055309
PMCPMC7003971
OpenAlexW2968796917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.